Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 28 (2014), Issue 1, Pages 35-40
http://dx.doi.org/10.1155/2014/367131
Original Article

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy

Curtis Cooper,1 Stephen Shafran,2 Susan Greenbloom,3 Robert Enns,4 John Farley,5 Nir Hilzenrat,6 Kurt Williams,7 Magdy Elkashab,8 Nabil Abadir,9 and Manuela Neuman10

1University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
2University of Alberta, Edmonton, Alberta, Canada
3Toronto Digestive Disease Associates, Toronto, Ontario, Canada
4St Paul’s Hospital, University of British Columbia, Canada
5Private Practice, Vancouver, British Columbia, Canada
6Jewish General Hospital and McGill University, Montreal, Quebec, Canada
7Royal University Hospital, Saskatoon, Saskatchewan, Canada
8Private practice, Toronto, Ontario, Canada
9Merck Canada Inc, Kirkland, Quebec, Canada
10University of Toronto, Toronto, Ontario, Canada

Received 10 September 2013; Accepted 15 September 2013

Copyright © 2014 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Curtis Cooper, Stephen Shafran, Susan Greenbloom, et al., “Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy,” Canadian Journal of Gastroenterology and Hepatology, vol. 28, no. 1, pp. 35-40, 2014. doi:10.1155/2014/367131